Efficacy and Safety of Azithromycine Versus  Amoxilline/Clavulanate in Treatment of Acute Exacerbation of   Chronic Bronchitis

Talib N. Aldamarchi, Ali

	Efficacy and Safety of Azithromycine Versus Amoxilline/Clavulanate in Treatment of Acute Exacerbation of Chronic Bronchitis
Medical Journal of Babylon
Article 1, Volume 6, Issue 2, 2009, Pages 207-216
Author
Ali Talib N. Aldamarchi
Abstract
This study has been done to compare the efficacy, safety, and tolerability of azithromycin and amoxicillin-clavulanate in the treatment of patients with infectious exacerbation of chronic bronchitis(AECB).This study was conducted at Al-Diwaniya Teaching Hospital and included 108 patients from 32 to 80 years of age. Those patients were randomized to receive either azithromycin (500 mg/day for three days, n = 56) or amoxicillin-clavulanate (625 mg two tablets twice daily for seven days, n = 52). The patients were evaluated at the study outset, on day 3-5, on day 7 and at long-term follow-up, day 28 . Based on the clinical evaluation of the signs and symptoms there were no differences between the groups treated with azithromycin or amoxicillin-clavulanate in terms of the percentages of cases in which the outcomes were classified as cure or improvement: 75% vs. 73.2% (p = >0.05) on day ten seven. The results of the present study confirm the efficacy and tolerability of azithromycin for the outpatient treatment of episodes of infectious exacerbation of COPD. In this context, it can be expected that the treatment with azithromycin will promote cure or clinical improvement in most patients, with acceptable toxicity and costs with no significant difference to the amoxicillin-clavulanate.

Statistics Article View: 88 PDF Download: 28